Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer

M Fukuoka, S Yano, G Giaccone, T Tamura… - Journal of clinical …, 2003 - ascopubs.org
Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839];
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …
被引用次数：3959 相关文章

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

M Fukuoka, S Yano, G Giaccone, T Tamura… - Journal of Clinical …, 2003 - cir.nii.ac.jp
< jats: p> Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa
[ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine …
[PDF] niph.go.jp

[PDF][PDF] Lung Cam cer

M Fukuoka, S Yano, G Giaccone… - Journal of dinal …, 2003 - mhlw-grants.niph.go.jp
Photodynamic therapy (PDT) is a form of cancer treatment which offers palliative therapy for
advanced cancer with obstructive tumors and the possibility of curing minimally invasive …

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)[corrected]

M Fukuoka, S Yano, G Giaccone… - Journal of clinical …, 2003 - pubmed.ncbi.nlm.nih.gov
Purpose To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839];
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)[corrected].

M Fukuoka, S Yano, G Giaccone, T Tamura… - Journal of Clinical …, 2003 - europepmc.org
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with
advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. - Abstract - Europe PMC …

[引用][C] Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer

M FUKUOKA, S YANO, R EEK, T HORAI… - Journal of clinical …, 2003 - pascal-francis.inist.fr
Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with
advanced non-small-cell lung cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis …

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

M Fukuoka, S Yano, G Giaccone, T Tamura… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839];
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer

M Fukuoka, S Yano, G Giaccone… - Journal of clinical …, 2023 - pubmed.ncbi.nlm.nih.gov
Purpose To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839];
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …

[引用][C] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)

M FUKUOKA - J Clin Oncol, 2003 - cir.nii.ac.jp
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with
advanced non-small-cell lung cancer (The IDEAL 1 Trial) | CiNii Research CiNii 国立情報学 …

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.

M Fukuoka, S Yano, G Giaccone, T Tamura… - Journal of Clinical …, 2023 - europepmc.org
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With
Advanced Non-Small-Cell Lung Cancer. - Abstract - Europe PMC Sign in | Create an account …